The Kirsten rat sarcoma viral oncogene homolog (KRAS) and the neuroblastoma RAS viral oncogene homolog (NRAS) mutations have been reported in <5% of MDS patients. This evidence concerns the gene KRAS and myelodysplastic syndrome.